Skip to main content

Table 4 Analysis of prognostic factors for progression-free survival (Cox proportional hazard with frailty)

From: The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the Rare Cancer Network

Factor

Univariate

Multivariate*

 

HR

(95% CI)

p-value

HR

(95% CI)

p-value

Radiation therapy

0.19

(0.11–0.31)

< 0.001

0.21*

(0.13 – 0.34)

< 0.001

Radiotherapy dose (>50 Gy)

0.60

(0.38–0.97)

0.028

   

Fraction size (≥ 2 Gy)

0.59

(0.37–0.95)

0.036

   

Resection margins*

1.07

(0.72–1.58)

n.s.

   

Indication radiotherapy

      

   Adjuvant radiotherapy

0.42

(0.25–0.72)

0.002

   

   Radiotherapy at recurrence

2.69

(1.63–4.41)

< 0.001

   

   Primary radiotherapy

0.36

(0.11–1.15)

n. s.

   

Tumour localization

      

   Head-neck

0.96

(0.46–2.00)

n.s.

   

   Trunk

0.67

(0.37–1.18)

n.s.

   

   Abdominal wall

0.42

(0.21–0.85)

0.017

0.28*

(0.15 – 0.53)

< 0.001

   Extremities*

2.5

(1.68–3.62)

< 0.001

   

Potential etiological factors

0.90

(0.61–1.32)

n.s.

   

Gender (male)

0.95

(0.62–1.45)

n.s.

   

Age (years)

0.99

(0.98–1.00)

n.s.

   
  1. *Without frailty calculated because Cox proportional hazard did not converge.
  2. Abbreviations: HR: hazard ratio; Cl: Confidence interval; n.s. : not significant.